5 mins | 30 mins | Hourly | Daily | Weekly |
---|---|---|---|---|
BUY | BUY | BUY | SELL | SELL |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MA5 | 1.93▼ | 1.91▲ | 1.90▲ | 1.92▼ | 2.28▼ |
MA10 | 1.93▲ | 1.90▲ | 1.85▲ | 2.10▼ | 2.36▼ |
MA20 | 1.91▲ | 1.85▲ | 1.83▲ | 2.22▼ | 1.86▲ |
MA50 | 1.90▲ | 1.86▲ | 2.04▼ | 2.35▼ | 1.33▲ |
MA100 | 1.86▲ | 2.05▼ | 2.18▼ | 1.79▲ | 1.47▲ |
MA200 | 1.83▲ | 2.19▼ | 2.30▼ | 1.35▲ | 1.98▼ |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MACD | 0.001▲ | 0.013▲ | 0.032▲ | -0.057▼ | -0.022▼ |
RSI | 56.401▲ | 60.850▲ | 52.266▲ | 39.809▼ | 52.266▲ |
STOCH | 68.651 | 73.215 | 86.673▲ | 32.510 | 32.595 |
WILL %R | -40.000 | -13.636▲ | -12.766▲ | -73.145 | -82.007▼ |
CCI | 17.051 | 125.895▲ | 101.017▲ | -111.133▼ | -146.872▼ |
Friday, August 15, 2025 04:46 AM
The Phase I trial of ADC CX-2051 in colorectal cancer will continue, based on a decision made by a safety committee.
|
Wednesday, August 13, 2025 05:22 AM
CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today provided an update on the CX-2051 Phase 1 stud ...
|
Tuesday, August 12, 2025 05:38 AM
Q2 2025 Earnings Call Transcript August 8, 2025 Operator: Good afternoon, everyone. Thank you for standing by. Welcome to the CytomX Therapeutics Second Quarter 2025 Financial Results Call. Please be ...
|
date | open | high | low | close | volume |
---|---|---|---|---|---|
15/08/25 | 1.78 | 1.96 | 1.775 | 1.91 | 9,889,414 |
14/08/25 | 1.80 | 1.81 | 1.72 | 1.76 | 6,542,386 |
13/08/25 | 1.90 | 2.08 | 1.77 | 1.775 | 10,539,484 |
12/08/25 | 2.24 | 2.265 | 1.831 | 1.86 | 11,205,822 |
11/08/25 | 2.32 | 2.4275 | 2.285 | 2.31 | 1,221,599 |
08/08/25 | 2.05 | 2.40 | 2.03 | 2.35 | 2,196,125 |
07/08/25 | 2.20 | 2.2299 | 2.07 | 2.10 | 2,734,115 |
06/08/25 | 2.39 | 2.39 | 2.155 | 2.17 | 1,927,671 |
05/08/25 | 2.37 | 2.40 | 2.35 | 2.37 | 783,598 |
04/08/25 | 2.39 | 2.40 | 2.345 | 2.39 | 1,180,612 |
|
|
||||
|
|
||||
|
|